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Background: The incidence of M. tuberculosis (MTB) and non tuberculous Mycobacterium species (NTMs) like M.
avium and M. kansasii has increased due to Human Immunodeficiency Virus (HIV) epidemic. Therefore accurate,
rapid and cost effective methods for the identification of these NTMs and MTB are greatly needed for appropriate
TB management. Thus in this study we evaluated the performance of Lightcycler® Mycobacterium detection assay
to detect MTB, M. avium and M. kansasii in sputum specimens.
Methods: A total of 241 baseline minimally processed sputum specimens from individual adult TB suspected
patients were analyzed by Mycobacterium detection assay (Real-time-PCR) on a LightCycler 480® while using liquid
culture as a reference standard.
Results: Real time PCR had a sensitivity of 100% (95% CI 96–100) and 100% (CI 19–100) for detection of MTB and M.
avium respectively. Additionally the assay had a specificity of 99% (95% CI 96–99) and 95% (95% CI 91–97) for
identification of MTB and M. avium respectively. The positive predictive value (PPV) for Real time PCR to identify MTB
and M. avium among the specimens was 98% (95% CI 94–99) and 15% (95% CI 2–45) respectively. The kappa statistics
for Real time PCR to identify MTB and M. avium was 0.9 (95% CI 0.9–1.0) and 0.3 (95% CI–0.03–0.5) respectively. The
median time to detection for Real time PCR assay was 2 hours while overall median time to detection for MGIT-positive
cultures was 8 days. The sample unit cost for Real time PCR was $ 12 compared to $ 20 for the reference liquid culture.
Conclusion: The Light cycler® Mycobacterium detection assay rapidly and correctly identified MTB and M avium thus
has the potential to be adopted in a clinical setting.
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Mycobacteria species cause a variety of illnesses includ-
ing pulmonary tuberculosis (PTB) which has profound
individual and public health implications [1]. The abso-
lute number of PTB cases occurring each year (9.4 mil-
lion) is currently greater than at any time in history and
the global incidence rate is estimated to have peaked [2].
The continued rise of PTB may be largely attributed to
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incidence of non-tuberculosis mycobacterial (NTM) dis-
ease in AIDS patients since the first cases in 1982 that
complicates the disease [4]. The commonest NTM’s as-
sociated with pulmonary infection among HIV patients
are M. avium complex, M. kansasii, M. abscessus and
M. fortuitum [5]. The disease caused by M. kansasii
often mimics pulmonary tuberculosis in signs and symp-
toms while M. avium causes disseminated disease. The
identification of NTMs has lagged behind because of
lack of infection awareness among physicians and micro-
biologists, lack of standardized criteria to define NTM
respiratory disease and poor laboratory infrastructure to
culture and identify NTMs. The lack of appropriate,entral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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undermines progress towards the 2015 millennium de-
velopment goals for TB control [6]. Therefore, this calls
for the need for evaluating more tools to use in accurate
diagnosis of TB.
A number of tools have been used in TB diagnosis, for
instance smear microscopy the most widely used test
has low sensitivity especially in patients with extra pul-
monary tuberculosis, those with HIV co-infection and
TB due to NTMs [7]. Nucleic acid amplification tests
such as PCR based assay have great promise for TB
diagnosis and rapid detection of drug resistance with
commercial assays widely used in developed countries
for over 20 years [8]. However despite their simplicity,
they are prone to PCR inhibitors, some tests require post
amplification procedures that increases the turn-around
time and some are limited by the DNA quantities in the
starting material [9,10]. Furthermore, since most of these
techniques require the isolates to be cultured first, this
will introduce growth competition in cases of mixed in-
fection and hence a selection bias. Recently WHO en-
dorsed GeneXpert MTB/RIF for use in the diagnosis of
TB in endemic countries [11] but it lacks markers for
identification of M. avium and M. kansasii that are
mainly associated with HIV patients. Therefore, the need
for an alternative method that can comprehensively de-
tect M. tuberculosis (MTB) and NTMs present in clinical
specimens.
In this study we evaluated the LightCycler® Mycobacter-
ium detection assay based on the principle of Real-time
PCR technology for the detection of M. tuberculosis, M.
avium and M. kansasii using species specific hybridization
probes designed based on the 16S ribosomal RNA (rRNA)
gene including the hyper variable region A [12,13]. We
performed a clinical evaluation on this assay to estimate
the cost effectiveness, turnaround time and analytical per-
formance for TB diagnostic potential.Methods
Clinical specimens
A total of 241 baseline sputum specimens collected as
part of a standard patient care were randomly selected
from clinical specimens sent to our TB laboratory be-
tween October 2012-February 2013.Ethics
The study protocol was reviewed and approved by the
Institutional Review Board (IRB) at Joint Clinical
Research Centre (JCRC). Individual informed consent was
not sought because the study was conducted on routine
samples only and it did not involve any intervention, add-
itional samples or change in patient management. A pa-
tient consent waiver was approved by the IRB of JCRC.Processing of sputum specimens
All specimens were decontaminated according to the
available laboratory protocol [14]. In brief, specimens
were 1:1 mixed with N-acetyl-L-cysteine (NALC)-NaOH
(final concentrations 1.5% NaOH, 0.7% NaCitrate, 0.25%
N-acetyl-cysteine) and put on plat form shaker (Thermo
scientific Inc. USA) at 60 rpm for 20 min. After
neutralization with 0.5 M phosphate buffer (pH 6.8) and
centrifugation (3000 × g for 20 min) in order to concen-
trate the mycobacteria, the sediment was re-suspended
with 2 ml phosphate buffer.
Of the sediment, 500 μl were inoculated into Myco-
bacteria Growth Indicator Tubes (MGIT™) (Becton-
Dickenson, Heidelberg, Germany) already supplemented
with 800 μl final concentration of 12.5 U/ml polymyxin
B, 1.25 mg/ml amphotericin B, 5 mg/ml nalidixic acid,
1.25 mg/ml trimethoprim and 1.25 mg/ml azlocillin
(PANTA) and incubated in the Bactec™ MGIT 960 sys-
tem (Becton, Dickinson and Company, Franklin Lakes,
NJ) according to the manual of the manufacturer. The
leftover suspension (500 to 1000 μl) was kept at 2–8°C
until further processing in the frame of the present
study. The tubes were automatically and continuously
monitored for growth and remained in the instrument
until it signaled positive for growth or negative at the
end of the 42-day incubation. All liquid cultures that
turned positive, were screened for acid fastness using
Ziehl Neelsen microscopy, inoculated on blood agar
plates to detect contaminants and then M. tubeculosis
confirmed using MPB64-protein based immuno-
chromatographic assay (capilia TB, TAUNS, Japan) fol-
lowing manufacturers’ guidelines. All the Mycobacteria
other than tuberculosis (MOTTs) cultures were screened
to confirm the presence of M. avium and M. kansasii
using DNA line probe assay (GenoType Mycobacterium
CM, Hain Lifesciences, Nehren, Germany) (see Figure 1).
Isolation of genomic DNA
In brief, 500 μl of the decontaminated sputum sample
was spun and pellet re-suspended in 20 μl of nuclease
free water; heat killed in a heat block set 95°C for 1 hour
to lyse the bacteria and later sonicated at 37 kHz (Elma
S30, Gottlieb-Daimler-Str. Singen, Germany) for 15 minutes.
The resultant genomic DNA in the supernatant was recov-
ered by centrifugation at 8000 g for 3 min for eventual use
in the Real time PCR assay.
Quality control
Reagents were aliquoted and each aliquot was used only
once. Sterile microfuge tubes and 96 PCR well plates for
Real time PCR assay use. Reagent preparation, DNA ex-
traction, DNA amplification and detection were per-
formed in separate rooms to avoid cross contamination
of amplicons.
Figure 1 GenoType Mycobacterium CM line probe assay results used to differentiate M. avium and M. kansasii from Mycobacteria other than
Tuberculosis (MOTTs).
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M. avium and M. kansasii) was included in each test
and distilled water was included as a negative test con-
trol. Uracil-N-glycosylase (UNG) was used in the ampli-
fication process to avoid post PCR DNA contamination.
Mycobacterium real time PCR
Real time PCR was performed on a LightCycler® 480 II
(Roche diagnostics, Mannheim, Germany) according to
the manufacturer’s instructions using light cycler myco-
bacterium detection assay. This assay comprised of two
major steps: (i) Amplification of internal control se-
quences and genomic target sequences (ii) melting curve
detection by florescence measurement at 640 nm. A
20 μl reaction mixture contained 4 μl of sample lysate
(or 4 μl of positive/negative control), 11 μl detection mix
(primers and probes), 4 μl of PCR master mix (Taq poly-
merase, DNTPs, Mg2+), 0.75 μl internal control and
0.25 μl uracil-DNA gylcosylase. Thermal cycling was as
follows: 10 min at 95°C, then 45 cycles of 10 sec 95°C,
10 sec 50°C and final extension of 20 sec at 72°C. Melting
curve detection to determine the melting temperatureM. avium
M. tub
Figure 2 Sigmoid amplification curves captured during anealing and elong
M. tuberculosis, M. avium or M. kansasii.(Tm) values for the target sequences was set as follows:
1 min at 95°C, 2 min at 40°C, 75°C continuous and then
cooling at 10 sec at 40°C.
Detection
The LightCycler® 480 II analyzed the samples in 2 steps:
(i) PCR amplification of the target region where the tar-
get amplicon for each sample were detected between the
annealing and elongation as sigmoid curves at 640 nm
(see Figure 2) (ii) Tm calling using the LightCycler
480®software to determine the melting temperature (Tm)
specific for each subtype in the samples (see Figure 3).
Range Tm included according to the manufacturer instruc-
tions include; 54.4 to 57.4°C for M. tuberculosis, 47.5 to
50.5°C for M. avium and 57.5 to 60.5°C for M, kansasii.
Analysis of data
The time that elapsed from MGIT sample inoculation
and incubation to MGIT culture positivity or negativity
was registered as the turnaround time (TAT) for liquid
culture. The time difference between the start and stop
time for each real time PCR run was used as theerculosis
M.kansasii
ation step by the Roche LightCycler 480 II indicating the detection of
M. avium
MTB M.kansasii
Figure 3 Melting temperature determination using Tm calling on LightCycler 480® software determining the different mycobacteria species
using temperature ranges; 54.4°C to 57.4°C for M. tuberculosis, 47.5°C to 50.5°C for M. avium and 57.5°C to 60.5°C for M. kansasii.
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ple cost between Real time PCR and liquid culture use
was achieved by comparing the requirements and their
costs to test 241 clinical specimens for identification of
M. tuberculosis, M. avium and M. kansasii.
Statistical data were entered and analyzed using Epi™
StatCal info version 7 software (CDC, Atlanta). The
values got were validated using statistical diagnostic soft-
ware MedCalc version 15.2.2 (MedCalc Software bvba,
Belgium).Results
Of the 241 patient sputum specimens (baseline), Real
time PCR identified 95 (39%) specimens as MTB, 13
(5%) as M. avium and 1M. kansasii (0.4%) while 132
(55%) were negative. For liquid culture that was used as
the reference standard, Capilia-neo TB (TAUNS) con-
firmed 94 (39%) MTB, 2 (0.8%) as M. avium and 14
(6%) were other Mycobacteria other than M. avium and
M. kansasii; all confirmed by genotype Mycobacterium
HAIN CM. 131 (54%) specimens were negative (no
growth) by liquid culture after 42 days of culture. (see
Table 1)
From 2X2 performance analysis (see Table 2), 96 (40%)
sputum samples were identified with mycobacterial spe-
cies; of these 94 (98%) as MTB and 2 (2%) as M. avium
by both methods. The remaining 145 (60%) specimens
were not identified as MTB, M. avium or M. kansasii




MTB M. avium M. kansasii RT PCR Negative To
Baseline 95 13 1 132 24Performance of Mycobacterium detection assay
When using baseline clinical specimens; the sensitivity
and specificity of Real time PCR in identifying MTB was
100% (CI; 96–100) and 99% (CI; 96–99) respectively
while for identification of M. avium; sensitivity and spe-
cificity was 100% (CI; 19–100) and 95% (CI; 91–97) re-
spectively (see Table 3). The positive predictive value
(PPV) and negative predictive value (NPV) for Real time
PCR to identify MTB at was 98% (CI; 94–99) and 100%
(CI; 97–100) respectively. Identification of M. avium
from baseline sputum specimens had a PPV and NPV of
15% (CI; 2–45) and 100% (CI; 98–100). Real time PCR
identification of one M. kansasii sputum specimen could
not be evaluated since liquid culture and genotype CM
failed to identify it.
Cost and time to detection
The sample unit cost for Mycobacterium real time PCR
assay was 12.2 US dollars as compared to 20 US dollars
used for liquid culture (see Table 4). The prices quoted
don’t include the cost of instruments; Roche LightCycler®
480 II (18,000$), BACTEC MGIT 960 (38,950$) and
HAIN twincubator (3,335$).
6 hours; 4 minutes was the entire time to run 241 clin-
ical specimens using Real time PCR assay in 6 runs giv-
ing an average time to detection for each run 1 hour;
40 minutes for identification of MTB, M. avium, M.
kansasii or negative. The time to detection for negative
liquid culture was 42 days (6 weeks) while that of posi-
tive cultures was 8 days (IQR 5.3–12.5).detection assay and liquid culture
Liquid culture
Capilia HAIN MGIT
tal MTB M. avium Other MOTTs No growth Total
1 94 2 14 131 241
Table 2 2x2 performance analysis of Real time PCR and Liquid culture
Mycobacterium detection assay
MTB M. avium M. kansasii Negative Total
Liquid culture Baseline MTB 94 - - 94
M. avium - 2 - - 2
Negative 1 11 1 132 145
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Global TB control efforts are based on rapid diagnosis
of disease cases followed by adequate treatment thus
prevent continued transmission. With increased inci-
dence of TB and non tuberculous disease infection espe-
cially among HIV patients, diagnostics with better
sensitivity and ability to identify M. tuberculosis and non
tuberculous mycobacteria are required for appropriate
management. Among the commonest non tuberculous
mycobacteria affecting HIV patients include M. avium
and M. kansasii which can be genomic DNA amplified
and specific products identified within the same reaction
using florescence monitoring by Real time PCR. The re-
cently WHO endorsed Real time PCR based assay;
GeneXpert® (Cepheid, Sunnyvale, USA) that offers rapid
identification of MTB and rifampicin resistance but
cannot identify M. avium and M. kansasii. This study
aimed at assessing Mycobacterium real time PCR assay
to identify M. tuberculosis, M. kansasii and M. avium
from patient clinical specimens at baseline diagnosis
and the data shows that Real time PCR was sensitive in
identifying MTB at baseline diagnosis and had a signifi-
cantly short turnaround time compared to liquid
culture.
By comparing Real time PCR with liquid culture as the
reference standard, its accuracy in identifying mycobac-
terial species from sputum samples has been demon-
strated in this study. Our study showed a high sensitivityTable 3 Performance of Real time PCR while using Liquid
culture as the reference standard
Baseline
MTB M. avium
Estimate 95% CI Estimate 95% CI
Sensitivity (%) 100 96–100 100 19–100
Specificity (%) 99 96–99 95 91–97
Prevalence (%) 39 33–45 0.8 0.1–2.9
PPV (%) 98 94–99 15 2–45
NPV (%) 100 97–100 100 98–100
Likelihood (+) 144 20–1018 21 12–38
Likelihood (−) 0.00 - 0.00 -
Kappa stat 0.9 0.9–1.0 0.3 -0.03–0.5(100%), specificity (99%) and positive predictive value
(98%) for identification of MTB from baseline sputum
specimens. Previous studies have described the use of
Real time PCR in the analysis of sputum samples at
baseline diagnosis and reported up 100% specificity for
identification of MTB [15,16]. Therefore this Real time
PCR assay is a suitable methodology for a clinician to
take a decision when identifying MTB from baseline
samples. This suggestion is further supported by the ex-
cellent agreement between Real time PCR and liquid
culture for identification of MTB (kappa statistics, 0.9).
However, Real time PCR assay may not be considered as
a replacement for culture of MTB given the observation
that it identified 1 specimen as MTB positive yet culture
indicated it as negative. Clinical decision in the context
of the patient may be important especially in the initi-
ation of anti-tuberculosis therapy. Nevertheless, the pos-
sibility that missed identification of the specimen can be
influenced by other factors such as DNA quality, DNA
concentration, extraction method, salt on buffer solution
among other factors that could affect amplification [17]
cannot be ruled out. These were however not evaluated
in this study.
Though this assay had high sensitivity and specificity
for identification of M. avium from the specimens, it
had a low positive predictive value (15%). This difference
is brought about by the discrepancies in the ability of
Real time PCR to identify certain species than HAIN
genotype Mycobacterium CM; for instance Real time
PCR identified 15M. avium, of which only 2 were iden-
tified as M. avium by liquid culture while using HAIN
genotype Mycobacterium CM reverse hybridization
assay. This is further supported by the theory of M.
avium cells being non-viable in liquid culture yet their
DNA was identified by Real time PCR assay. Further-
more, one species of M. kansasii was identified by Real
time PCR but could not be classified as a mycobacter-
ium species by HAIN genotype Mycobacterium CM fol-
lowing liquid culture. Though another study with a
larger sample size is needed to study this discrepancy, a
study in South Africa reported M. scrofulaceum (human
lymph node isolate) and M. flavescens to give a false
positive signal for M. avium and M. kansasii respectively
due to the similarity in the hyper variable region A of
16S RNA [13].
Table 4 Costs comparison between Real time PCR assay and liquid culture
Items Liquid culture Mycobacterium detection assay
Quantity (Box) US cost ($) Quantity US cost ($)
Bactec 960 MGIT culture media 3 1,458
Bactec 960 MGIT supplement 2 232
ZN carbolfuschin stain (BD) 1 79
ZN Decolorizer stain (BD) 1 60
Methylene Blue stain (BD) 1 70
Capilia TB Neo 1 1,200
Genotype mycobacterium CM kit 1 1,800
Light cycler Mycobacterium detection kit 1 2,500
PCR plates 3 450
Total 4,829 2,950
US Unit cost ($) (241 samples) 20.0 12.2
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time to detection (1 hour; 40 minutes) significantly
lower than that of liquid culture which is comparable to
other Real time technology like GeneXpert (2 hours)
[18] This greatly reduces the time to initiation of anti-
tuberculosis therapy and lost to follow-up cases due to
delays in making diagnosis [19]. In this study it was esti-
mated that the unit specimen cost to test using reference
standard was almost twice more expensive than use of
Real time PCR assay, although the capital costs to buy
the respective equipment was not included. In a South
African nationwide feasibility study done by Boehme
et al. [20] indicated that Real time PCR assays may be
more expensive than smear microscopy but the costs
were similar to sputum culture. A larger study may be
needed to assess the cost effectiveness of this assay com-
pared to liquid culture. Since this assay has amplification
and detection done by the Roche 480 II instrument,
there are limited chances of assay contamination than
other assays like DNA line probe assays that involve fur-
ther manipulations after amplification. With the demon-
strated advantages of using this technique such as
capacity to identify the M. tuberculosis and M. avium,
high through put ability, cheaper cost than liquid culture
and short turnaround time puts this Real time PCR
assay at the forefront of molecular techniques to guide
TB management especially in highly endemic mycobac-
terial diseased countries like Uganda.Conclusion
The Mycobacterium Real time PCR assay correctly iden-
tified the majority of the culture confirmed M. tubercu-
losis with high specificity though identification of M.
avium and M. kansasii needs to be assessed further es-
pecially in high risk population. The utility of this assayfor TB diagnosis was comparable with liquid culture;
thus it can be adopted in a clinical setting. This assay
proved to be a rapid and cost-effective test compared to
liquid culture for identification of M. tuberculosis and
M. avium from clinical specimens.
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